Protagenic Therapeutics, Inc.\new financial data

Symbol
PTIX, PTIXW on Nasdaq
Location
149 Fifth Avenue, Suite 500, New York, NY
State of incorporation
DE
Fiscal year end
December 31
Former names
Atrinsic, Inc. (to 6/20/2016), NEW MOTION, INC. (to 6/30/2009), MPLC, Inc. (to 4/2/2007), MILLBROOK PRESS INC (to 5/23/2005)
Latest financial report
10-K - Q4 2024 - Mar 31, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 250 % -51.4%
Debt-to-equity 61.3 % +156%
Return On Assets -294 % -258%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 7.53M shares +69.7%
Common Stock, Shares, Outstanding 7.24M shares +63.3%
Entity Public Float 4.04M USD -54%
Common Stock, Value, Issued 725 USD +63.3%
Weighted Average Number of Shares Outstanding, Basic 4.9M shares +12.8%
Weighted Average Number of Shares Outstanding, Diluted 4.9M shares +12.8%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 0 USD
Research and Development Expense 3.84M USD +25.5%
General and Administrative Expense 1.76M USD +45.7%
Operating Income (Loss) -5.7M USD -25.9%
Nonoperating Income (Expense) 176K USD
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -5.53M USD -10.5%
Net Income (Loss) Attributable to Parent -5.53M USD -10.5%
Earnings Per Share, Basic -1.13 USD/shares +1.74%
Earnings Per Share, Diluted -1.13 USD/shares +1.74%

Balance Sheet

Label TTM Value / Value Unit Change %
Marketable Securities, Current 1.59M USD -78.8%
Assets, Current 1.88M USD -55.2%
Property, Plant and Equipment, Net 73K USD -40.8%
Assets 1.96M USD -54.8%
Liabilities, Current 943K USD +43.9%
Liabilities 943K USD +43.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax -130K USD -14.4%
Retained Earnings (Accumulated Deficit) -36.3M USD -18%
Stockholders' Equity Attributable to Parent 1.01M USD -72.4%
Liabilities and Equity 1.96M USD -54.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.66M USD -346%
Net Cash Provided by (Used in) Investing Activities 1.2M USD +308%
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 7.24M shares +63.3%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -456K USD -495%
Deferred Tax Assets, Valuation Allowance 8.71M USD +23.2%
Deferred Tax Assets, Gross 8.71M USD +23.2%
Depreciation 50.3K USD +78.2%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -5.54M USD -24.9%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 20M shares 0%
Additional Paid in Capital 37.4M USD +8.35%
Preferred Stock, Shares Outstanding 0 shares
Interest Expense 108K USD -21.7%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%